What is the 13F Pro Quality Score for DGX?

13F Pro ranks QUEST DIAGNOSTICS INC (DGX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DGX's current score at https://13fpro.ai/company/DGX (free sign-up required for the full ranking).

Where does 13F Pro source DGX data?

All QUEST DIAGNOSTICS INC fundamentals and ownership data come directly from SEC EDGAR. QUEST DIAGNOSTICS INC files with the SEC under CIK 1022079. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DGX in?

QUEST DIAGNOSTICS INC (DGX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives DGX's revenue?

Per QUEST DIAGNOSTICS INC's latest 10-Q filed with the SEC on 2026-07-23, the biggest revenue drivers are: Diagnostic Information Services (DIS) ($2,978M, +10.3% YoY); Diagnostic Solutions (DS) ($65M, +4.3% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/DGX.

What are DGX's largest expenses?

QUEST DIAGNOSTICS INC's latest 10-Q reports these as the largest expense items: Cost of services ($2,016M, +10.9% YoY); Selling, general and administrative ($529M, +9.0% YoY); Amortization of intangible assets ($38M, -4.4% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is DGX research updated on 13F Pro?

DGX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

QUEST DIAGNOSTICS INC(DGX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1022079 DGX stock profile & AI dashboard →

13F Pro Quality Score

69.0/100

Rank #287 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

62.5/100

Profitability

61.0/100

Balance Sheet

75.0/100

Earnings Quality

81.3/100

Free Cash Flow

59.1/100

Institutional Flow

71.8/100

Revenue Scale

87.7/100

Dilution Risk

63.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why DGX Scores 69/100

exact factor attribution · 2026-09-11

DGX's composite is driven by scale and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+5.7 pts

88th pct

Earnings quality

+3.1 pts

81th pct

Revenue growth

+2.5 pts

63th pct

Capital efficiency

+2.5 pts

75th pct

Profitability

+1.6 pts

61th pct

Free cash flow

+1.4 pts

59th pct

Institutional flow

+1.1 pts

72th pct

Shareholder dilution

+0.7 pts

64th pct

Earnings growth

+0.4 pts

59th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

DGX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for QUEST DIAGNOSTICS INC (DGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DGX at 69.0/100 on a 32-signal composite quality model, placing it at rank #287 of 2,961 stocks — the top 10% of the AI-ranked universe. DGX scores in the top quartile across revenue scale (87.7), earnings quality (81.3), balance sheet strength (75.0). Based on the latest XBRL financial filings (Q2 2026), QUEST DIAGNOSTICS INC reports quarterly revenue of $3.0B, net income of $320.0M, an operating margin of 15.1%. Top institutional holders of DGX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. DGX trades on the NYSE exchange and files with the SEC under CIK 1022079. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for QUEST DIAGNOSTICS INC directly from SEC EDGAR. QUEST DIAGNOSTICS INC's 13F Pro composite quality score has ranged between 48 and 79 since 2021, currently 69.0 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

What's Driving DGX's Business? Latest 10-Q Breakdown

✓ 26/26 datapoints verified

AI-extracted from QUEST DIAGNOSTICS INC's 10-Q filed 2026-07-23 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net revenues rose 10.2% to $3,043M as DIS requisition volume jumped 13.1%, while revenue per requisition fell 2.8% on Corewell Health and Fresenius routine-test mix.

Biggest Revenue Drivers

Diagnostic Information Services (DIS)$2,978M+10.3% YoY

Principally driven by organic growth of 10.1%; volume up 13.1% with ~9 points from Corewell Health and Fresenius Medical Care testing

Diagnostic Solutions (DS)$65M+4.3% YoY

Principally consistent with the prior year period

Biggest Revenue Drivers

Total revenue: $3,043M+10.2% YoY

Diagnostic Information Services (DIS)$2,978M+10.3% YoY

Principally driven by organic growth of 10.1%; volume up 13.1% with ~9 points from Corewell Health and Fresenius Medical Care testing

Diagnostic Solutions (DS)$65M+4.3% YoY

Principally consistent with the prior year period

Largest Expense Items

Cost of services$2,016M+10.9% YoY

Higher compensation costs and increased supplies expense reflecting higher testing volumes, partially offset by Invigorate cost savings

Selling, general and administrative$529M+9.0% YoY

Primarily driven by higher compensation costs

Amortization of intangible assets$38M-4.4% YoY

Principally consistent with the prior year period

Margins: Operating income was $459M, or 15.1% of net revenues versus 15.9% a year ago; cost of services rose to 66.3% of revenues from 65.8%, as compensation and supplies outpaced Invigorate savings.

Watch Items from the Filing

Revenue per requisition fell 2.8%, driven by Corewell Health and Fresenius Medical Care mix, which includes a greater proportion of routine tests; excluding them it rose about 3%.
Roughly 9 of the 13.1% DIS volume growth came from two relationships — Corewell Health and Fresenius dialysis clinics; underlying organic volume grew about 4%.
Payer mix shifted: healthcare insurers fell to 37% of net revenues from 40%, while client payers rose to 32% from 30% and patients to 13% from 12%.
Days sales outstanding rose to 50 days from 48 at December 31, 2025 and 47 a year ago; accounts receivable consumed $259M of operating cash year-to-date.
Reserves for general and professional liability claims totaled $174M, including Ireland pap smear screening claims; legal matter reserves were $17M with AMCA data-incident class actions ongoing.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$3.0B

Net Income

Q2 2026

$320.0M

Free Cash Flow

Q2 2026

$459.0M

Operating Margin

Q2 2026

15.1%

ROIC

Q2 2026

13.9%

D/E Ratio

Q2 2026

0.75

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+11.8% YoY

$11.04BFY 2025

FY22 $9.88BFY23 $9.25BFY24 $9.87BFY25 $11.04B

Net Income

+13.9% YoY

$992.0MFY 2025

FY22 $946.0MFY23 $854.0MFY24 $871.0MFY25 $992.0M

Operating Income

+15.6% YoY

$1.56BFY 2025

FY22 $1.43BFY23 $1.26BFY24 $1.35BFY25 $1.56B

EPS (Diluted)

+13.8% YoY

$8.75FY 2025

FY22 $7.97FY23 $7.49FY24 $7.69FY25 $8.75

Total Assets

+0.4% YoY

$16.23BFY 2025

FY22 $12.84BFY23 $14.02BFY24 $16.15BFY25 $16.23B

Total Debt

-9.4% YoY

$6.17BFY 2025

FY22 $3.98BFY23 $5.02BFY24 $6.82BFY25 $6.17B

Op. Cash Flow

+41.4% YoY

$1.89BFY 2025

FY22 $1.72BFY23 $1.27BFY24 $1.33BFY25 $1.89B

Free Cash Flow

+49.5% YoY

$1.36BFY 2025

FY22 $1.31BFY23 $864.0MFY24 $909.0MFY25 $1.36B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$11.04B +11.8%	$9.87B +6.7%	$9.25B -6.4%	$9.88B -8.4%	$10.79B +14.3%	$9.44B
Net Income	$992.0M +13.9%	$871.0M +2.0%	$854.0M -9.7%	$946.0M -52.6%	$2.00B +39.4%	$1.43B
Operating Income	$1.56B +15.6%	$1.35B +6.7%	$1.26B -11.6%	$1.43B -40.0%	$2.38B +20.8%	$1.97B
EPS (Diluted)	$8.75 +13.8%	$7.69 +2.7%	$7.49 -6.0%	$7.97 -48.7%	$15.55 +48.5%	$10.47
Total Assets	$16.23B +0.4%	$16.15B +15.2%	$14.02B +9.2%	$12.84B -5.7%	$13.61B -3.0%	$14.03B
Total Debt	$6.17B -9.4%	$6.82B +35.9%	$5.02B +26.0%	$3.98B -0.8%	$4.01B -0.1%	$4.02B
Operating Cash Flow	$1.89B +41.4%	$1.33B +4.9%	$1.27B -26.0%	$1.72B -23.1%	$2.23B +11.4%	$2.00B
Free Cash Flow	$1.36B +49.5%	$909.0M +5.2%	$864.0M -34.2%	$1.31B -28.2%	$1.83B +15.3%	$1.59B

Get alerted when DGX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for QUEST DIAGNOSTICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DGX

BlackRock, Inc.
$2.0B9,275,411 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.5B7,233,394 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.3B6,131,045 sh
STATE STREET CORP
$1.2B5,516,643 sh
PRICE T ROWE ASSOCIATES INC /MD/
$1.2B5,444,986 sh
Boston Partners
$1.0B4,744,473 sh
JPMORGAN CHASE & CO
$748.6M3,520,438 sh
GEODE CAPITAL MANAGEMENT, LLC
$662.6M3,137,873 sh
MORGAN STANLEY
$521.5M2,460,497 sh
EdgePoint Investment Group Inc.
$476.4M2,247,568 sh

Fund	Value	Shares
BlackRock, Inc.	$2.0B	9,275,411
VANGUARD CAPITAL MANAGEMENT LLC	$1.5B	7,233,394
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.3B	6,131,045
STATE STREET CORP	$1.2B	5,516,643
PRICE T ROWE ASSOCIATES INC /MD/	$1.2B	5,444,986
Boston Partners	$1.0B	4,744,473
JPMORGAN CHASE & CO	$748.6M	3,520,438
GEODE CAPITAL MANAGEMENT, LLC	$662.6M	3,137,873
MORGAN STANLEY	$521.5M	2,460,497
EdgePoint Investment Group Inc.	$476.4M	2,247,568

Companies Similar to DGX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

LABCORP HOLDINGS INC.

AI score

Very similar · 25 shared holders

Boston Partners Willis Investment Counsel AVIVA PLC

MDT

Medtronic plc

AI score

Very similar · 29 shared holders

Boston Partners M&G Plc CRAWFORD INVESTMENT COUNSEL INC

ABT

ABBOTT LABORATORIES

AI score

Very similar · 27 shared holders

Grantham, Mayo, Van Otterloo & Co. LLC M&G Plc PFA Pension, Forsikringsaktieselskab

HCA

HCA Healthcare, Inc.

AI score

Very similar · 25 shared holders

PFA Pension, Forsikringsaktieselskab SEB Asset Management AB APG Asset Management N.V.

SYK

STRYKER CORP

AI score

Very similar · 22 shared holders

Boston Partners Clark Capital Management Group, Inc.PFA Pension, Forsikringsaktieselskab

CVS

CVS HEALTH Corp

AI score

Very similar · 32 shared holders

DAVIS SELECTED ADVISERS Boston Partners Grantham, Mayo, Van Otterloo & Co. LLC

ZBH

ZIMMER BIOMET HOLDINGS, INC.

AI score

Very similar · 26 shared holders

Boston Partners AVIVA PLC M&G Plc

BSX

BOSTON SCIENTIFIC CORP

AI score

Very similar · 26 shared holders

SEB Asset Management AB Integral Health Asset Management, LLC PFA Pension, Forsikringsaktieselskab

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DGX on your watchlist

Track score changes the day QUEST DIAGNOSTICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DGX a good stock to buy?

13F Pro's AI-powered analysis of QUEST DIAGNOSTICS INC (DGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DGX are available on the DGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DGX is classified as a large company.

Which hedge funds own DGX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of QUEST DIAGNOSTICS INC's investment landscape.